Overview
These therapies remove amyloid plaque and modestly slow the rate of decline in early disease. They do not reverse symptoms or stop progression.
Realistic expectations
- Benefit is a slower rate of decline, measured over 18 months in trials
- Individuals may not notice a difference day to day
- Treatment requires substantial time commitment and monitoring
Practical requirements
- Biomarker confirmation before starting
- Access to an infusion center and MRI
- Insurance authorization
- Specialist oversight
Medically reviewed. Last reviewed August 2026. This page is educational information, not individualized medical advice.